<DOC>
	<DOCNO>NCT00935792</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth cancer cell block signal molecule need cell growth . Monoclonal antibody , alemtuzumab , bind kill malignant lymphocyte . PURPOSE : This phase I/II trial study side effect best dose everolimus give together alemtuzumab see well work treat patient recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL ) .</brief_summary>
	<brief_title>Everolimus Alemtuzumab Treating Patients With Recurrent Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Test safety tolerability combination everolimus alemtuzumab . ( Phase I ) II . Determine maximum tolerate dose everolimus combination . ( Phase I ) III . Assess rate overall responses patient relapsed/refractory CLL treatment maximum tolerate dose everolimus together standard dose alemtuzumab use conventional NCI-WG 1996 response criterion . ( Phase II ) IV . To assess complete response combination regimen use conventional NCI-WG 1996 criterion expand definition response , include CT scan chest-abdomen-pelvis , immunohistochemical analysis residual disease bone marrow , sensitive flow cytometry minimal residual disease patient complete clinical remission . V. To monitor assess toxicity regimen . SECONDARY OBJECTIVES : I . To determine overall progression-free survival , duration response , time next treatment . II . To assess correlation individual prognostic marker ( 17p- , p53 gene mutation , 11q- , unmutated VH gene , use VH3-21 , ZAP70+ , CD38+ , CD49d , B2 microglobulin ) clinical outcome . III . Serial measurement clinical status lymphocyte count test rate reduction CLL tumor burden . TERTIARY OBJECTIVES : I . Determine effect everolimus sensitivity CLL cell alemtuzumab CDC ADCC . II . Determine effect everolimus CLL cell-stroma interaction . III . Detail vivo effect everolimus-alemtuzumab regimen critical aspect immune system CLL . OUTLINE : This phase I , dose escalation study everolimus follow phase II study . Patients receive oral everolimus thrice weekly 9 week alemtuzumab subcutaneously thrice weekly 7 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 44 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Inclusion Diagnosis CLL manifest minimum threshold peripheral lymphocyte count &gt; 5 x 10^9/L ( CLL variant ) OR palpable adenopathy &gt; = 1cm clinically palpable splenomegaly ( SLL variant ) ; AND immunophenotypic demonstration population B lymphocytes ( defined CD19+ ) monoclonal ( light chain exclusion ) CLL diagnose cell &gt; = 3 follow characteristic : CD5+ , CD23+ , dim surface light chain expression , dim surface CD20 expression , AND FISH analysis negative IGH/CCND1 and/or immunostaining negative cyclin D1 expression exclude mantle cell lymphoma Previous treatment CLL Progressive disease : symptomatic CLL ( weight loss &gt; 10 % within 6 month , extreme fatigue , fever &gt; 38.5 C , drench night sweat without evidence infection ) OR evidence progressive bone marrow failure ( hemoglobin &lt; 11g/dL , platelet count &lt; 100 x 10^9/L ) OR massive ( &gt; 6 cm leave costal margin ) progressive palpable splenomegaly OR massive ( &gt; 10 cm ) measurable progressive lymphadenopathy Please contact study investigator and/or consult protocol document specific detail laboratory criterion CD52 expression CLL cell Willing provide mandatory biospecimen sample research study require protocol Negative serum pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Willingness return enrol institution followup ECOG Performance Status ( PS ) 0 , 1 , 2Exceptions : Grade 3 allow cause CLL comorbidities Provide inform write consent Life expectancy &gt; = 3 month Exclusion Any follow comorbid condition : NYHA class IIIIV heart disease , recent myocardial infarction ( &lt; 6 month prior registration ) , uncontrolled infection , infection human immunodeficiency virus ( HIV/AIDS ) , serological evidence active hepatitis B infection ( HBsAg HBeAg positive ) positive hepatitis C serology , severe immunosuppression regimen may occur Evidence active autoimmune hemolytic anemia , immune thrombocytopenia , pure red blood cell aplasia Other active primary malignancy require treatment limit survival = &lt; 2 year Any major surgery = &lt; 4 week prior registration Concurrent investigational drug therapy Any following : pregnant woman , nurse woman , men woman childbearing potential unwilling employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , abstinence , etc . ) Concomitant use follow CYP3A4 strong inhibitor : Clarithromycin , Nefazodone , Telithromycin , Aprepitant , Indinavir , Nelfinavir , Diltiazem , Borisonazole , Itrazonazole , Ritonavir , Erythromycin , Ketoconazole , Saquinavir , Fluconazole ( may use drug level monitor ) Patients know bleed diathesis ( congenital bleeding disorder affect platelet function and/or coagulation include von Willebrand 's Disease ) Severely impaired lung function define spirometry DLCO 50 % normal predict value and/or O2 saturation 88 % less rest room air Receiving anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>hematopoietic cancer</keyword>
	<keyword>lymphoid cancer</keyword>
</DOC>